Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III seamless randomized double-blind excipient-controlled study of Xianglei Tangzu Gao for Wagner grade II diabetic foot ulcers
CTR20241325Phase 3Active
- Sponsor
- Unibio
- Start
- Sep 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Fespixon in diabetic foot ulcer (DFU), sponsored by Unibio. Started Sep 2024; status: active.
02
Drugs
Fespixon
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on CTR20241325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241325.